Rivaroxaban for the Prevention of Stroke and Systemic Embolism in People with Atrial Fibrillation (TA256)

Technology Appraisal Guidance No. 256

Source: National Institute for Health and Care Excellence

1. Guidance

1.1  Rivaroxaban is recommended as an option for the prevention of stroke and systemic embolism within its licensed indication, that is, in people with nonvalvular atrial fibrillation with one or more risk factors such as:

  • congestive heart failure
  • hypertension
  • age 75 years or older
  • diabetes mellitus
  • prior stroke or transient ischaemic attack.

1.2  The decision about whether to start treatment with rivaroxaban should be made after an  informed discussion between the clinician and the person about the risks and benefits of rivaroxaban compared with warfarin. For people who are taking warfarin, the potential risks and benefits of switching to rivaroxaban should be considered in light of their level of international normalised ratio (INR) control.

The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA256

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email:nice@nice.org.uk

Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Issue Date: May 2012

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in